Sana Biotechnology Inc
$ 4.41
-2.65%
26 Dec - close price
- Market Cap 1,174,675,000 USD
- Current Price $ 4.41
- High / Low $ 4.52 / 4.33
- Stock P/E N/A
- Book Value 0.74
- EPS -0.96
- Next Earning Report 2026-03-24
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.24 %
- ROE -0.96 %
- 52 Week High 6.55
- 52 Week Low 1.26
About
Sana Biotechnology Inc., headquartered in Seattle, Washington, is a pioneering biotech company focused on engineered cell therapies designed to tackle substantial unmet medical challenges across various diseases. Utilizing its cutting-edge cell-engineering platform, Sana is actively advancing the fields of gene therapy and regenerative medicine, aiming to revolutionize treatment approaches and improve patient outcomes significantly. The company boasts a promising pipeline supported by strong research and development initiatives, making it an attractive prospect for institutional investors looking to invest in transformative biotherapeutic innovations.
Analyst Target Price
$8.57
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-11 | 2025-05-06 | 2025-02-26 | 2024-11-06 | 2024-08-08 | 2024-05-08 | 2024-02-29 | 2023-11-08 | 2023-08-03 | 2023-05-08 | 2023-03-16 |
| Reported EPS | -0.16 | -0.39 | -0.2 | -0.23 | -0.25 | -0.32 | -0.32 | -0.41 | 0.02 | -0.59 | -0.43 | -0.38 |
| Estimated EPS | -0.18 | -0.2 | -0.2 | -0.2428 | -0.27 | -0.28 | -0.32 | -0.38 | -0.45 | -0.43 | -0.45 | -0.51 |
| Surprise | 0.02 | -0.19 | 0 | 0.0128 | 0.02 | -0.04 | 0 | -0.03 | 0.47 | -0.16 | 0.02 | 0.13 |
| Surprise Percentage | 11.1111% | -95% | 0% | 5.2718% | 7.4074% | -14.2857% | 0% | -7.8947% | 104.4444% | -37.2093% | 4.4444% | 25.4902% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-24 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.1444 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SANA
2025-12-28 15:09:13
This article is a placeholder and does not contain substantive content. It appears to be related to a Yahoo cookie consent page. There is no information available about Sana Biotechnology or gene editing in this provided text.
2025-12-27 18:09:13
Sana Biotechnology is developing an 80,000-square-foot manufacturing facility in Bothell, replacing a larger Fremont, California facility, expected to save the company over $100 million. ZenLedger, a cryptocurrency tax software company, will remain remote after a $15 million Series B funding round, emphasizing productivity over office politics. Mason, a Seattle-based smart product builder, has hired former Meta/Oculus veteran Brian Hook as its Chief Technology Officer.
2025-12-22 18:08:40
Corient Private Wealth LLC significantly increased its stake in Sana Biotechnology (NASDAQ:SANA) by 264.7% in Q2, acquiring 1,136,000 shares valued at approximately $3.10 million. Despite analysts issuing varied ratings, with an average "Moderate Buy" and a price target of $8.33, Sana Biotechnology recently exceeded EPS expectations but remains unprofitable. Institutional investors hold a substantial 88.23% of the company's stock, which currently trades around $4.36 with a market capitalization of $1.16 billion.
2025-12-14 12:09:38
Marex Group plc has acquired a new stake of 3,817,780 shares in Sana Biotechnology (NASDAQ:SANA) during the second quarter, valued at approximately $10.42 million. Institutional ownership of Sana Biotechnology is significant, with 88.23% held by hedge funds and other institutions. The company recently reported Q2 earnings of ($0.15) per share, beating estimates by $0.03, and analysts have an average "Moderate Buy" rating with a target price of $8.33.
2025-12-14 11:09:38
Nine analysts have given Sana Biotechnology, Inc. (NASDAQ:SANA) a "Moderate Buy" consensus rating, with an average 12-month price target of $8.33. The company's stock opened at $5.14, with a market cap of $1.37 billion, and analysts expect an EPS of -1.16 for the current fiscal year. Institutional investors hold a significant stake in SANA, with several increasing their positions in the last quarter.
2025-12-11 21:09:11
Sana Biotechnology reported reduced losses and a strong cash position for the third quarter of 2024. The company's net loss decreased to $81.7 million from $100.9 million in the prior year, attributed to lower research and development as well as general and administrative expenses. Sana Biotechnology maintains a robust liquidity of $440.3 million, expected to fund operations into mid-2026.
